Saı̈d M. Sebti

20.7k citations

250 papers · 16.7k indexed · 1 hit paper · h-index 73

Molecular Biology top 0.2%
Oncology top 0.2%
Immunology top 1%
Cancer Research top 0.5%
Organic Chemistry top 1%

Co-authors: Andrew D. Hamilton Jiazhi Sun Yimin Qian Michelle A. Blaskovich Richard Jove James Turkson Nicholas J. Lawrence Norbert Berndt
Topics: Cancer-related Molecular Pathways (75 papers)Protein Kinase Regulation and GTPase Signaling (59 papers)PI3K/AKT/mTOR signaling in cancer (45 papers)
Cited by: Oncology Molecular Biology Toxicology
Journals: Nature Proceedings of the National Academy of Sciences Journal of the American Chemical Society
Partner nations: United States China France

In The Last Decade

Saı̈d M. Sebti

248 papers receiving 16.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

2007 616 citations Shumin Zhang, Wayne C. Guida et al. profile →

Peers

Countries citing papers authored by Saı̈d M. Sebti

Since Specialization

Citations

This map shows the geographic impact of Saı̈d M. Sebti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saı̈d M. Sebti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saı̈d M. Sebti more than expected).

Fields of papers citing papers by Saı̈d M. Sebti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saı̈d M. Sebti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saı̈d M. Sebti. The network helps show where Saı̈d M. Sebti may publish in the future.

Co-authorship network of co-authors of Saı̈d M. Sebti

This figure shows the co-authorship network connecting the top 25 collaborators of Saı̈d M. Sebti. A scholar is included among the top collaborators of Saı̈d M. Sebti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saı̈d M. Sebti. Saı̈d M. Sebti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Design and Evaluation of Bivalent K‐Ras Inhibitors That Target the CAAX Binding Site and the Acidic Surface of Farnesyltransferase and Geranylgeranyltransferase I 2025 ·Chemistry - A European Journal ·(unknown),(unknown),(unknown),(unknown),Yoshihisa Inoue,(unknown),Takeyuki Suzuki,Saı̈d M. Sebti,Junko Ohkanda	1
2	Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer 2021 ·Clinical Cancer Research ·Aslamuzzaman Kazi,Liwei Chen,Shengyan Xiang,(unknown),Hua Yang,Francisca Beato,Bin Fang,Terence M. Williams,Kazim Husain,Patrick W. Underwood,Jason B. Fleming,Mokenge P. Malafa,Eric A. Welsh,John M. Koomen,José G. Treviño,Saı̈d M. Sebti	25
3	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results 2021 ·Clinical Cancer Research ·Joseph Pidala,Kelly Walton,Hany Elmariah,Jongphil Kim,Asmita Mishra,Nelli Bejanyan,Taiga Nishihori,Farhad Khimani,Lia Perez,Rawan Faramand,Marco L. Davila,Michael L. Nieder,Elizabeth M. Sagatys,Shernan G. Holtan,Nicholas J. Lawrence,Harshani R. Lawrence,Bruce R. Blazar,Claudio Anasetti,Saı̈d M. Sebti,Brian C. Betts	15
4	CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function 2020 ·Cancer Immunology Research ·Justin C. Boucher,Gongbo Li,Hiroshi Kotani,Maria L. Cabral,Dylan Morrissey,Sae Bom Lee,Kristen Spitler,(unknown),(unknown),Bishwas Shrestha,Bin Yu,Aslamuzzaman Kazi,Xuefeng Wang,Saı̈d M. Sebti,Marco L. Davila	48
5	Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors 2019 ·Clinical Cancer Research ·Aslamuzzaman Kazi,Shengyan Xiang,Hua Yang,Liwei Chen,Perry Kennedy,Muhammad Ayaz,Steven Fletcher,Christopher T. Cummings,Harshani R. Lawrence,Francisca Beato,Ya’an Kang,Michael P. Kim,Andrea E. Delitto,Patrick W. Underwood,Jason B. Fleming,José G. Treviño,Andrew D. Hamilton,Saı̈d M. Sebti	53
6	A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation 2013 ·Cancer Research ·Xiaolei Zhang,Ying Sun,Roberta Pireddu,Hua Yang,(unknown),Harshani R. Lawrence,Wayne C. Guida,Nicholas J. Lawrence,Saı̈d M. Sebti	122
7	Selective Disruption of Rb–Raf-1 Kinase Interaction Inhibits Pancreatic Adenocarcinoma Growth Irrespective of Gemcitabine Sensitivity 2013 ·Molecular Cancer Therapeutics ·José G. Treviño,Monika Verma,Sandeep Singh,Smitha Pillai,Dongyu Zhang,(unknown),Saı̈d M. Sebti,Nicholas J. Lawrence,Barbara A. Centeno,Srikumar Chellappan	6
8	Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity 2012 ·Cancer Research ·Fengdong Cheng,Hongwei Wang,Pedro Horna,Zi Wang,Bijal Shah,Eva Sahakian,Karrune Woan,Alejandro Villagra,Javier Pinilla‐Ibarz,Saı̈d M. Sebti,Mitchell R. Smith,Jianguo Tao,Eduardo M. Sotomayor	15
9	RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer 2012 ·Cancer Research ·(unknown),(unknown),Roberta Pireddu,Ying Sun,Nan Sun,Mathew P. Martin,E. Schönbrunn,Nicholas J. Lawrence,Saı̈d M. Sebti	123
10	Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice 2011 ·Clinical Cancer Research ·Maria E. Balasis,(unknown),Y. Ann Chen,William J. Fulp,Domenico Coppola,Andrew D. Hamilton,Jin Q. Cheng,Saı̈d M. Sebti	55
11	Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins 2009 ·Molecular Cancer Therapeutics ·Jun Wei,Shinichi Kitada,Michele F. Rega,Aras Emdadi,Hongbin Yuan,Jason Cellitti,John L. Stebbins,Dayong Zhai,Jiazhi Sun,Li Yang,Russell Dahl,Ziming Zhang,Bainan Wu,Si Wang,(unknown),Nicholas J. Lawrence,Saı̈d M. Sebti,John C. Reed,Maurizio Pellecchia	51
12	A Small Molecule Disruptor of Rb/Raf-1 Interaction Inhibits Cell Proliferation, Angiogenesis, and Growth of Human Tumor Xenografts in Nude Mice 2008 ·Cancer Research ·Rebecca Kinkade,Piyali Dasgupta,Adam Carie,(unknown),Melanie A. Carless,Smitha Pillai,Nicholas J. Lawrence,Saı̈d M. Sebti,Srikumar Chellappan	45
13	Delta-tocotrienol is the most bioactive natural tocotrienol in the prevention of pancreatic cancer transformation 2008 ·Cancer Research ·Kazim Husain,R François,(unknown),Saı̈d M. Sebti,Mokenge P. Malafa	2
14	Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide 2006 ·Journal of Clinical Oncology ·Joseph A. Sparano,Stacy L. Moulder,Aslamuzzaman Kazi,Linda T. Vahdat,Tianhong Li,Christine Pellegrino,P.N. Munster,Mokenge P. Malafa,David Lee,(unknown),Una Hopkins,Dawn L. Hershman,James R. Wright,Saı̈d M. Sebti	54
15	Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-x _L 2005 ·Journal of the American Chemical Society ·Hang Yin,(unknown),(unknown),Olaf Kutzki,Hyung Soon Park,Brendan P. Orner,Justin T. Ernst,Hong‐Gang Wang,Saı̈d M. Sebti,Andrew D. Hamilton	166
16	A Novel Platinum Compound Inhibits Constitutive Stat3 Signaling and Induces Cell Cycle Arrest and Apoptosis of Malignant Cells 2005 ·Journal of Biological Chemistry ·James Turkson,Shumin Zhang,Linda Mora,(unknown),Saı̈d M. Sebti,Richard Jove	135
17	Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt 2004 ·Cancer Research ·Lin Yang,Han C. Dan,Mei Sun,Qiyuan Liu,(unknown),Richard I. Feldman,Andrew D. Hamilton,Mark A. Polokoff,Santo V. Nicosia,Meenhard Herlyn,Saı̈d M. Sebti,Jin Q. Cheng	360
18	Blocked Pathways: FTIs Shut Down Oncogene Signals 2003 ·The Oncologist ·Saı̈d M. Sebti	19
19	Requirement for Ras/Rac1-Mediated p38 and c-Jun N-Terminal Kinase Signaling in Stat3 Transcriptional Activity Induced by the Src Oncoprotein 1999 ·Molecular and Cellular Biology ·James Turkson,Tammy Bowman,Jalila Adnane,Yi Zhang,Julie Y. Djeu,Madhavi Sekharam,David A. Frank,Lawrence B. Holzman,Jie Wu,Saı̈d M. Sebti,Richard Jove	226
20	Farnesyltransferase inhibitors: Anti-Ras drugs for cancer treatment 1996 ·Anti-Cancer Drugs ·Channing J. Der,Adrienne D. Cox,Saı̈d M. Sebti,Andrew D. Hamilton	2

About Saı̈d M. Sebti

Saı̈d M. Sebti is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 250 papers that have together received 16.7k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (75 papers), Protein Kinase Regulation and GTPase Signaling (59 papers) and PI3K/AKT/mTOR signaling in cancer (45 papers). The work is most often cited by research in Oncology (6.7k citations), Molecular Biology (11.0k citations) and Toxicology (467 citations). Saı̈d M. Sebti has collaborated with scholars based in United States, China and France. Frequent co-authors include Andrew D. Hamilton, Jiazhi Sun, Yimin Qian, Michelle A. Blaskovich, Richard Jove, James Turkson, Nicholas J. Lawrence, Norbert Berndt, Harshani R. Lawrence and Domenico Coppola. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact